Date: 2016-04-04
Type of information: Joint-venture agreement
Compound: Intrexon T1D Partners
Company: Intrexon (USA - MD) White Rock Capital Partners
Therapeutic area: Autoimmune diseases - Metabolic diseases
Type agreement: joint-venture
Action mechanism:
Disease: type 1 diabetes
Details: * On April 4, 2016, Intrexon Corporation announced the formation of Intrexon T1D Partners, LLC, a joint venture with a select group of external investors led by White Rock Capital Partners, LP, to develop ActoBiotics® based antigen-specific immunotherapy to treat type 1 diabetes in humans. The objective of the program is to create an easy-to-take pill for people afflicted with type 1 diabetes to halt autoimmune-induced damage, both for early stage patients before they become insulin dependent and also for certain advanced stage patients to potentially prevent the requirement for insulin to be administered externally. As detailed in the peer-reviewed publication, Oral Delivery of Glutamic Acid Decarboxylase (GAD)-65 and IL10 by Lactococcus lactis Reverses Diabetes in Recent-Onset NOD Mice, ActoBiotics® therapeutics co-expressing the anti-inflammatory cytokine interleukin-10 (IL-10) demonstrated reversal of T1D following oral administration. Introduction of these auto-antigens induced antigen-specific suppressive regulatory T cells specifically at the inflamed target organ and antigen-draining lymph nodes, validating the potential of ActoBiotics® based immunotherapy for intervention in T1D. Through an Exclusive Channel Collaboration agreement, Intrexon received a technology access fee of $10 million. Intrexon T1D Partners, LLC, in which Intrexon owns a fifty percent interest, will be responsible for all costs related to the development, manufacture, approval and commercialization of the product.
Financial terms:
Latest news:
